insulpatch, page-47

HI CSY,

SORRY TO TAKE SO LONG BUT I HAVE A RIPPER EAR AND JAW ACHE, I NEED THE TPM OXYPATCH MYSELF ATM. i HAVE NEVER KNOWN PAIN LIKE THIS. OFF TO THE EYE AND EAR IN THE MORNING.

NOW TO YOUR QUESTIONS

INSULIN

INSULIN IS A DIFFICULT PRODUCT TO WORK. ONLY BECAUSE IT IS A LARGE PROTEIN NOTHING ELSE.

POH's PRODUCT WILL NOT REPLACE INJECTIONS OR THE PUMP. WE WILL NOT MANAGE THE UPS AND DOWNS OF INSULIN METABOLISM.

THE PRODUCT WILL SIMPLY PROVIDE A BACKGROUND STEADY STATE AMOUNT OF INSULIN.

THESE STUDIES ARE EASY TO CONDUCT - SIMILAR TO THE NOVO-NORDISK ONCE A DAY PEN.... AND AS THE PRODUCT WILL BE A PATCH MUCH MORE PATIENT FRIENDLY.

THE TESTING PROTOCOLS ARE QUITE STRAIGHT FORWARD.

POH WILL CONDUCT CLAMPING EXPERIMENTS TO ASSESS THE EFFICACY OF THE PRODUCT. YOU DO NOT NEED TO CONDUCT DOUBLE-BLINDED CROSS OVER STUDIES (THIS IS TOTALLY WRONG!! YOU HAVE OBVIOUSLY NEVER CONDUCTED STUDIES IN THESE PATIENTS) THIS IS COMPLETELY INCORRECT.

POH WILL ONLY COMPARE OUR PRODUCT TO THE INJECTION OR LONG ACTING PEN ONLY TO ASSESS AND COMPARE BIOAVAILABILITY.

ALL THESE STUDIES CAN BE EASILY CONDUCTED THE MAJOR ISSUE IS THAT THEY COST A LOT OF MONEY BECAUSE WHEN WORKING WITH DIABETIC PATIENTS YOU NEED TO HAVE MANY SAFETY PARAMETERS INCLUDED AS PART OF THE STUDY.

THIS IS WHY THEY ARE TAKING IT STEP AT A TIME AND SPENDING MORE TIME OPTIMIZING THE PRODUCT AND PROGRAM USING DIABETIC RATS. THIS ANIMAL MODEL IS GENETICALLY IDENTICAL TO A TYPE 1 PATIENT.

OXYPATCH

ONCE AGAIN TOTALLY IN-CORRECT. FENTANYL IS THE ONLY NARCOTIC PAIN PATCH PRODUCT ON THE MARKET. FENTANYL HAS MANY SIDE EFFECTS AND CANNOT BE READILY USED AND IS NOT WELL TOLERATED AS OXYCODONE. IT HAS MANY ISSUES. IT HAS A FDA RED-LABEL WARNING.

OXYCODONE IS THE GOLD STANDARD IN PAIN MANAGEMENT.

IT HAS A GREAT SAFETY PROFILE AND CHRONIC USE DOESNT CAUSE TOO MANY ISSUES (UNLIKE FENTANYL)..........POH's OXYCODONE PRODUCT WILL BE INDICATED FOR CHRONIC USE.

IT WILL HAVE WELL-ESTABLISHED ANTI-ABUSE PROPERTIES AND WILL BE THE FIRST IN CLASS AND IN ITS SCHEDULE.

IT WILL REVOLUTIONISE THE MANAGEMENT OF PAIN SIMPLY BY REDUCING OR REMOVING THE GI TRACT RELATED SIDE EFFECTS, REMOVING THE PEAKS AND TROUGHS -IE BREAKTHROUGH PAIN.

MANAGING BREAKTHROUGH PAIN IS THE HOLY GRAIL IN PAIN MANAGEMENT.

JUST LOOK AT PURDUE THEIR ORAL OXYCONTIN IS A MULTI-BILLION DOLLAR BLOCKBUSTER. PATIENTS HAVE TO TAKE UP TO 3 4 TABLETS A DAY JUST TO CONTROL PAIN.

POH AIMS TO TRANSDERMALISE SOME OF THIS MARKET. EVERY PAIN CLINICIAN THAT I HAVE SPOKEN TO HAS CLEARLY SAID THAT TPM/OXYCODONE CAN EASILY REPLACE THE ORAL TABLET.

THERE IS MUCH MORE AND POHS TRIALS HAVE ALREADY PROVEN THE AFOREMENTIONED OVER AND OVER. THIS IS WHY AUSTRALIAS LARGEST BIO CO CSL HAS ASKED POH TO TRIAL ITS PROTEINS TRANSDERMALLY.
THEY ARE IMPRESSED BY THE DELIVERY PALTFORM AND HAVE SAID SO AS STATED BY THEIR CHIEF SCIENTIST IN JUNE 2009 WHEN ANNOUNCING THE COLLABORATION OF POH AND CSL.

I SEE YOU ARE FORM PERTH, NOT ANYWHERE NEAR LEEDERVILLE ARE YOU?